Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study
Esther Aspinall(Glasgow Caledonian University), Margaret Hellard(Burnet Institute), Rachel Sacks‐Davis(Burnet Institute), Sharon Hutchinson(Glasgow Caledonian University), Jason Grebely(UNSW Sydney), Tim Spelman(Peter Doherty Institute), Amanda Weir(Health Protection Scotland), Peter Higgs(Curtin University)
Cited by 51
Related Papers
Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees
|The Lancet|2016|648
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
|Hepatology|2013|393
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence
|Clinical Infectious Diseases|2009|234